Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 14, 2016

Eisai wins approval to use Aricept for DLB treatment in Philippines

HI-Eisai Pharmaceutical, a subsidiary of Eisai in the Philippines, has obtained approval for a new indication Aricept (donepezil hydrochloride) to treat dementia with Lewy bodies (DLB).

HI-Eisai Pharmaceutical, a subsidiary of Eisai in the Philippines, has obtained approval for a new indication Aricept (donepezil hydrochloride) to treat dementia with Lewy bodies (DLB).

DLB is a degenerative form of dementia discovered in Japan that is pathologically characterised by decreased neurons in the brain and brainstem and the appearance of vast numbers of Lewy bodies.

It is believed that DLB is difficult to be diagnosed because the disease is characterised by symptoms such as cognitive fluctuations, visual hallucinations and Parkinsonism in addition to progressive cognitive impairment.

DLB is considered to be one of the major types of dementia worldwide, alongside Alzheimer’s disease and vascular dementia.

"The anti-Alzheimer’s agent Aricept can now be used to treat DLB in the Philippines, in addition to Japan."

The anti-Alzheimer’s agent Aricept can now be used to treat DLB in the Philippines, in addition to Japan.

Aricept was first approved in Japan in September 2014 to treat DLB.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Nearly 400,000 people in the Philippines are affected by dementia, the company said.

Earlier in 1999, Aricept was initially launched as a treatment for Alzheimer’s disease in the Philippines.

Later, the medication obtained approval to treat vascular dementia, and for other formulations including orally disintegrating tablets.

Developed by Eisai and Pfizer, Aricept acts as a centrally acting reversible acetylcholinesterase inhibitor.

The application was submitted in November 2015 to seek approval for DLB in the Philippines and is based on the clinical trial data from Japan. It was subsequently approved in February this year.

Additionally, a similar application is currently undergoing regulatory review in Thailand.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU